[Bevacizumab in age-related macular degeneration: more injections, better vision, at lower costs].

Q4 Medicine

Nederlands tijdschrift voor geneeskunde Pub Date : 2025-02-25

Haras Mhmud, Odette A M Tigchelaar-Besling, Jeroen P Vermeulen, Frank D Verbraak, Daniel Barthelmes, Mark Gillies, Theodorus L Ponsioen, Caroline C W Klaver

{"title":"[Bevacizumab in age-related macular degeneration: more injections, better vision, at lower costs].","authors":"Haras Mhmud, Odette A M Tigchelaar-Besling, Jeroen P Vermeulen, Frank D Verbraak, Daniel Barthelmes, Mark Gillies, Theodorus L Ponsioen, Caroline C W Klaver","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: To study the long-term outcomes of anti-VEGF treatment for neovascular age-related macular degeneration (nAMD) in the Netherlands, where off-label bevacizumab is used as the first choice, compared to countries that typically use ranibizumab or aflibercept.Design: Prospective real-world observational study.Methods: A total of 1,617 Dutch eyes were compared with 8,667 eyes from a reference group derived from 13 socio-economically comparable countries. The primary outcome was the mean visual acuity (VA) measured at annual intervals up to 60 months. Secondary outcomes included injection frequency and the rate of switching to an alternative injection type.Results: Dutch eyes exhibited higher VA, received two additional injections annually and switched to alternative treatments more frequently (65.2% vs. 50.1%) and sooner (14.6 months vs. 17.9 months).Conclusion: Dutch patients achieved higher VA after 60 months compared to the reference group. This higher VA was associated with a greater number of injections and a tendency to switch to a more expensive registered anti-VEGF injection type.","PeriodicalId":18903,"journal":{"name":"Nederlands tijdschrift voor geneeskunde","volume":"169 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nederlands tijdschrift voor geneeskunde","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To study the long-term outcomes of anti-VEGF treatment for neovascular age-related macular degeneration (nAMD) in the Netherlands, where off-label bevacizumab is used as the first choice, compared to countries that typically use ranibizumab or aflibercept.

Design: Prospective real-world observational study.

Methods: A total of 1,617 Dutch eyes were compared with 8,667 eyes from a reference group derived from 13 socio-economically comparable countries. The primary outcome was the mean visual acuity (VA) measured at annual intervals up to 60 months. Secondary outcomes included injection frequency and the rate of switching to an alternative injection type.

Results: Dutch eyes exhibited higher VA, received two additional injections annually and switched to alternative treatments more frequently (65.2% vs. 50.1%) and sooner (14.6 months vs. 17.9 months).

Conclusion: Dutch patients achieved higher VA after 60 months compared to the reference group. This higher VA was associated with a greater number of injections and a tendency to switch to a more expensive registered anti-VEGF injection type.

本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Nederlands tijdschrift voor geneeskunde Medicine-Medicine (all)

CiteScore

0.30

自引率

0.00%

发文量

302

期刊介绍： Het NTVG staat bekend als hét wetenschappelijke algemene medische tijdschrift. De lange historie en de degelijkheid maken het tijdschrift tot een bolwerk van medische wetenschap in druk. Ook door de goede leesbaarheid draagt het tijdschrift bij aan de voortdurende dialoog over de geneeskunde.